The addition of these newly identified urinary methylated DNA markers to our previously developed methylated DNA markers, mRASSF1a and mGSTP1, in combination with AFP showed an increased sensitivity from 30 to 80% for HCC screening as compared to AFP alone. The gene discussed is AFP; the disease is hepatocellular carcinoma.